From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar
Lunai Bioworks (NASDAQ: LNAI) shares surged over 15% to around $1 after announcing preclinical success in pancreatic cancer immunotherapy on Nov. 5, 2025. The stock remains down more than 85% year-over-year and trades near all-time lows after a 10:1 reverse split in September. Lunai is pre-revenue, posted a $178 million net loss over the past year, and faces severe liquidity issues.